The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC.
 
Kathryn Cecilia Arbour
No Relationships to Disclose
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology
Research Funding - Guardant Health
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Genentech/Roche
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Paul K. Paik
Honoraria - ARIAD; Bristol-Myers Squibb; Celgene; Lilly
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Celgene; Lilly
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
 
Ai Ni
No Relationships to Disclose
 
Andrew Plodkowski
No Relationships to Disclose
 
Gregory J. Riely
Consulting or Advisory Role - Genentech; Novartis; Novartis; Roche
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Incyte; Lilly